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A novel inhibitor of influenza virus growth in tissue culture was identified and characterized. This compound (BMY-27709)
has an IC50 of 3– 8 mM for A/WSN/33 virus growth in a multicycle replication assay and is active against all H1 and H2
subtype viruses tested. However, BMY-27709 was found to be inactive against H3 subtype viruses, as well as influenza
B/Lee/40 virus. BMY-27709 was also found to act against H1 and H2 viruses early in infection, suggesting that the target
for inhibition is the hemagglutinin protein. This was confirmed through the use of reassortant viruses and the isolation of
a virus resistant to BMY-27709. The resistant virus isolated contained a phenylalanine to serine change at amino acid 110
of the HA2 subunit. That this single mutation was responsible for the acquisition of resistance to BMY-27709 was proven
through reverse genetics, as transfectant virus containing only this change was shown to be resistant to BMY-27709, while
the control virus without this mutation remained sensitive. BMY-27709 is able to inhibit virus-induced red blood cell hemolysis,
suggesting that it blocks the membrane fusion function of hemagglutinin. These experiments further illustrate that the
hemagglutinin protein of influenza virus is a viable target for the discovery and development of small molecule inhibitors
of virus growth. q 1996 Academic Press, Inc.
INTRODUCTION replication occurs (Krug et al., 1989). After replication,
viral genomes leave the nucleus and progeny virus parti-
Influenza virus is the etiologic agent of an acute respi-
cles are assembled and budded from the cellular mem-
ratory infection which continues to represent a major
brane of the infected cell (Wiley and Skehel, 1987; Roth
threat to human health in the world (Murphy and Webster, et al., 1989).
1990). In the United States alone, there are more than Viral proteins which provide essential functions during
10,000 excess deaths yearly as a result of primary influ- the life cycle of influenza virus are potential targets for
enza virus followed by secondary bacterial infections (Lui the development of antiviral agents. Several agents in-
and Kendal, 1987). At present, the most effective means volved in the infectious cycle have already been docu-
of combating influenza is through seasonal vaccination mented (Hayden, 1989; Pinto et al., 1992; Hay, 1992; von
initiatives, which provides limited protection (Murphy and Itsztein et al., 1993). The approved drugs amantadine and
Webster, 1990; Center for Disease Control, 1992). In addi- rimantadine, along with the newly described BL-1743,
tion, antiviral agents such as amantadine and rimantad- have been shown to inhibit influenza A virus infection by
ine are available, but are of limited use due to spectrum blocking the ion channel activity of the M2 protein (Pinto
and resistance problems (Hayden et al., 1989). et al., 1992; Hay, 1992; Kurtz et al., 1995; Tu et al., 1996).
Influenza virus is an enveloped virus, containing a seg- The ion channel activity of the M2 protein is necessary
mented, single-stranded RNA genome of negative polar- for the uncoating of the viral particles prior to release to
ity (Palese, 1977). The virus initiates infection through the cytoplasm (Hay, 1992; Pinto et al., 1995). The polymer-
a receptor–ligand interaction and subsequent receptor- ase of influenza virus is another attractive viral target. It
mediated endocytosis (Wilson et al., 1981; Weis et al., consists of a complex of three proteins (PB1, PB2, and
1988; Steinhauer et al., 1992). After entry, the components PA), which, along with the nucleoprotein (NP), are viral
of the viral particle are disassembled in the endosome, factors required for transcription and replication of the
where the low pH induces the irreversible conformational viral genome (Krug et al., 1989; Huang et al., 1990). A
change of hemagglutinin (HA), resulting in the fusion of number of small molecule inhibitors of the polymerase
the viral and endosomal membranes (Stegmann and Hel- have recently been identified which can inhibit the endo-
enius, 1993; Helenius, 1992; White, 1990, 1992, Wiley and nuclease activity associated with the polymerase (To-
Skehel, 1987). The viral genome is then released from massini et al., 1994; Hensens et al., 1995; Tomassini et
the endosome and transported into the nucleus, where al., 1996; Hastings et al., 1996; Cianci et al., 1996).
Recently, strategies of structure-based drug design
have been used to model inhibitors of influenza A virus.1 To whom correspondence and reprint requests should be addressed.
Fax: (203) 284-6088. E-mail: Guangxiang_Luo@ccmail.bms.com. A successful example of this strategy was the modifica-
660042-6822/96 $18.00
Copyright q 1996 by Academic Press, Inc.
All rights of reproduction in any form reserved.
AID VY 8270 / 6a25$$$161 10-31-96 15:00:14 viras AP: Virology
67HEMAGGLUTININ-SPECIFIC INHIBITOR OF INFLUENZA A VIRUS
tion of sialic acid to produce neuraminidase inhibitors K. Subbaro and Brian Murphy and was amplified in
MDCK cells. Influenza A/Texas/36/91 virus was kindly(von Itzstein et al., 1993). The neuraminidase (NA) func-
tions to remove the sialic acid from potential receptors, provided by Dr. Frederick Hayden. Influenza A/Taiwan/
1/86 was a gift from Dr. Nancy Cox. All viruses werewhich helps the budding of progeny virus from the cell
membrane and promotes the spread of the virus in the titrated in MDCK cells except influenza A/WSN/33 virus,
which was titrated in MDBK cells. Chicken red bloodrespiratory tract (Colman, 1989; Palese et al., 1974; Klenk
and Rott, 1988; Air and Laver, 1989). These inhibitors are cells (RBC) were purchased from Spafas (Preston, CT).
The RBCs were washed twice with 11 PBS (GIBCO,highly active and selective, with activity in animal models
and in clinical settings (von Itzstein et al., 1993; Colman, Gaithersburg, MD) and prepared to 2% solution in PBS.
1994; Woods et al., 1993; Ryan et al., 1994, 1995, Hayden
Tissue culture-based growth assayet al., 1996). Another study used computer-assisted drug
design to identify small molecule inhibitors which are A multicycle tissue culture growth followed estab-
modeled to dock in a pocket in the hemagglutinin mole- lished protocols (Sladowski et al., 1993). MDBK (105) cells
cule in an attempt to interfere with the low pH-induced were seeded onto 96-well plates 14 hr prior to virus
conformational change (Bodian et al., 1993). The hemag- infection. Approximately 30 to 50 PFU of influenza A/
glutinin plays a key role in the binding of virus to the WSN/33 virus in 100 ml of 2% FBS-containing MEM was
sialic acid receptor on the cell surface and also triggers used to infect each well of MDBK cells. At 1 hr postinfec-
the fusion of viral and endosomal membranes through a tion, an equal volume of MEM-2% FBS medium con-
low pH-induced conformational change (Steinhauer et taining test compounds was added to the cells. An unin-
al., 1992; Helinius, 1992; White, 1990, 1992). It was sug- fected 96-well plate of MDBK cells was used as control.
gested that HA is a unique target for anti-influenza virus After 3 days incubation at 377, 20 ml of MTT (3-[4,5-Di-
drug discovery (Carr and Kim, 1993, 1994), which was methylthiazol-2-yl ]-2,5-diphenyltetrazolium bromide;Thia-
validated by recent identification of H3 fusion inhibitors solyl blue) solution (7.5 mg/ml in PBS) was added to each
(Bodian et al., 1993). well and incubated for an additional 2 hr. The media
In this report, we characterize a compound which spe- was removed and the cells were treated with 100 ml
cifically inhibits the growth of influenza A virus in tissue of acidified isopropanol. The extent of living cells was
culture. It exhibits no activity against influenza B/Lee/40 measured through absorbance of MTT by using a pro-
virus and other viruses such as vesicular stomatitis virus grammed Multiskan Mcc/340 (Titertek) as described
(VSV) or herpes simplex virus (HSV). Also, with respect (Sladowski et al., 1993). The percentage of cells pro-
to human viruses, its spectrum of anti-influenza activity tected from virus infection was calculated as follows:
is restricted to H1 and H2 subtype HA viruses, as it is
inactive against H3 subtype viruses tested. The results
cell protection (%)  O.D.mock 0 O.D.Flu
O.D.CPN 0 O.D.Flu 1 100%described in this study also demonstrate that BMY-27709functions by blocking viral–cell membrane fusion.
(O.D.CPN  virus plus compound; O.D.Flu  virus only;MATERIALS AND METHODS
O.D.mock  compound only).
Cells and viruses
Single and multicycle growth
Madin–Darby bovine kidney (MDBK) cells were grown
in reinforced MEM (REM) medium (Whittaker, Walk- In order to test the effects of BMY-27709 (4-amino-5-
chloro-2-hydroxy-N-9AaH-octahydro-6b-methyl-2H-ersville, MA) containing 10% fetal bovine serum (FBS,
GIBCO, Gaithersburg, MD). The virus-infected MDBK quinolizin-2a-benzamide) on single cycle virus growth,
MDBK cells in 35-mm2 dishes were infected with influ-cells were maintained in REM with 0.42% bovine albumin
(BA) solution. Madin–Darby canine kidney (MDCK) cells enza A/WSN/33 virus at a multiplicity of infection of ap-
proximately 2. At 1 hr p.i., the media was removed andwere grown in minimal essential medium (MEM) con-
taining 10% FBS, and the virus-infected cells were main- cells were washed twice with PBS. BMY-27709 was
added to cells either during infection (0 hr), or at 1, 3, ortained in MEM containing BA. Influenza A/WSN/33 virus
(H1N1), BMY-27709-resistant A/WSN/33 virus, and a re- 5 hr p.i.. The cells were incubated for 14 hr and the virus
yield in the medium was determined by plaque assay inassortant virus, HK-WSN (H3N1) (Schulman and Palese,
1976), were grown in MDBK cells. Influenza A/PR/8 virus MDBK cells. For multicycle growth experiments, MDBK
cells (2 1 106) in 35-mm2 dishes were infected with 30(H1N1), A/Japan/305/57 (H2N2), A/Singapore/57, A/HK/
8/68 (H3N2), and X31 (H3N2) viruses (Wilson et al., 1981) to 50 PFU of viruses at 377 for 1 hr. The virus-infected
MDBK cells were incubated with varying amounts ofwere propagated in 11-day-old embryonated hen eggs
as described (Barrett and Inglis, 1985). Influenza BMY-27709 at 377C for three days. The virus yield was
then determined by plaque assay in MDBK cells.A/Udorn/307/72 (H3N2) was generously provided by Drs.
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Plaque reduction assay used to rescue the cloned HA gene back into virus.
Briefly, MDBK cells were infected with HK-WSN (H3N1)Either MDBK or MDCK cells in 35 mm2 dishes (2 1
virus as helper virus. At 1 hr p.i., HA RNP complexes106) were infected with 50 to 100 PFU of viruses and
were transfected into MDBK cells as described (Enamiincubated at 377C for one hour. The media was removed
and Palese, 1991; Li et al., 1992). The RNP complexesand the cells were covered with 2.5 ml of agar-overlay
were reconstituted in vitro by incubation of 1 mg Ear I-medium containing various amounts of BMY-27709. Influ-
linearized DNA of pUC19-HA1 with 10 ml (0.5 mg/ml) ofenza A/PR/8 (H1N1), A/Taiwan/86 (H1N1), A/Texas/91
viral polymerase proteins and nucleoprotein (NP) in the(H1N1), A/Japan/57 (H2N2), A/Singapore/57 (H2N2), A/
presence of T7 RNA polymerase and ribonucleotides (En-Vic/75 (H3N2), and A/HK/68 (H3N2) viruses were plaqued
ami and Palese, 1991). At approximately 18 hr post-on MDCK cells in the presence of 10 mg/ml trypsin
transfection, the supernatant of RNP-transfected MDBK(GIBCO, Gaithersburg, MD). Influenza A/WSN/33 (H1N1)
cells was used to infect fresh MDBK cells. The transfec-and BMY-27709 resistant viruses were plaqued on MDBK
tant virus (H1 subtype HA) containing the HA RNA of thecells without trypsin. After 2 to 3 days incubation, cells
resistant virus was isolated through two passages andwere stained with 0.1% crystal violet solution.
a final plaque purification in the presence of polyclonal
Isolation of resistant virus antisera against A/HK/8/68 virus (Li et al., 1992).
Influenza A/WSN/33 virus was used to infect cells at
Hemolysis inhibition assaya multiplicity of infection of less than 0.001 and propa-
gated in the presence of 38 mM BMY-27709 in MDBK Hemolysis inhibition assays were modified from those
cells for 3 days. The viral yield was then passaged once described previously (Bodian et al., 1993). Briefly, 100 ml
more at low multiplicity in MDBK cells in the presence of (about 6 mg of protein) virus was incubated with an equal
75.8 mM BMY-27709. After this second passage, resistant volume of PBS containing various concentrations of
virus was isolated by plaquing in MDBK cells in the pres- BMY-27709 at 377 for 1 hr. 200 ml of a 2.0% solution of
ence of 75.8 mM BMY-27709. Virus was amplified from chicken red blood cell in PBS was added to the reaction
individual plaques in the presence of 75.8 mM of the and further incubated at 377 for 10 min. The virus-bound
compound in MDBK cells. chicken RBCs were pelleted by centrifugation at 1.6 k
rpm for 8 min. The RBC pellet was resuspended in 450Virus preparation, RNA extraction, and HA cDNA
ml of low pH PBS buffer (pH 5.0 { 0.05) containing thecloning
corresponding concentration of BMY-27709, and incu-
Plaque-purified viruses were amplified in MDBK cells
bated at 377 for 15 min. The reaction was neutralized to
and purified through 30 –60% sucrose gradients. Virion
pH 7.0 { 0.2 by the addition of 1 N NaOH. Cell debris
RNA (vRNA) was then extracted as described previously
and unlysed cells were pelleted down through centrifu-
(Luo et al., 1992). One microgram of total vRNA of BMY-
gation at 2 K rpm for 8 min. 300 ml of supernatant was
27709-resistant virus was used for reverse transcription
transferred to 96-well tissue culture plate (Corning, New
using RNase H minus MLV reverse transcriptase (BRL,
York) for measurement of optical density at a wavelength
Gaithersburg, MD) and HA-specific primer, Ksp-HAv (5*-
of 540 nm using a programmed Multiscan MCC/340 (Ti-
GGTCTAGACTCTTCGAGCAAAAGCAGGGGAAAATAA-
tertek) plate reader.
AAAC-3* ). The HA cDNA was amplified by polymerase
chain reaction (PCR) using Deep Vent DNA polymerase
RESULTS(BioLabs, Beverly, MA) and oligonucleotides Ksp-HAv
and T7-inf (5*-GGTACCGGTACCTTAATACGACTCACT- Anti-viral activity of BMY-27709
ATAAGTAGAAACAAG-3* ) as primers. The PCR fragment
BMY-27709 (4-amino-5-chloro-2-hydroxy-N-9AaH-oc-was digested with KpnI and XbaI and inserted into the
tahydro-6b-methyl-2H-quinolizin-2a-benzamide) is a be-appropriate window of pUC19. Two independent cDNA
nzamide derivative which is part of the Bristol-Myersclones (designated as pUC19-HA1 and pUC19-HA10) of
Squibb proprietary chemical collection. It was initiallythe HA gene of the resistant virus were sequenced using
identified as active against influenza A/WSN/33 virus inthe dideoxynucleotide chain termination method and a
a multicycle growth assay. BMY-27709 was subsequentlyseries of oligonucleotides as primers. The mutations
characterized by a number of features with respect to itswhich cause amino acid changes found in the cDNA
antiviral activity and specificity. Figure 1 illustrates theclones were verified by direct RNA sequencing (Sanger
antiviral activity of BMY-27709 in an MTT-based assayet al., 1977).
performed in MDBK cells. The IC50 of this compound
RNP transfection and isolation of transfectant viruses against influenza A/WSN/33 virus is 3–8 mM. In addition,
BMY-27709 showed little cytoxicity, as the CC50 was mea-Reverse genetics (Luytjes et al., 1989; Enami et al.,
1990; and for review see Luo and Palese, 1992) were sured to be greater than 600 mM (data not shown). In a
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medium including various concentrations of BMY-27709.
The results are presented in Fig. 2A. BMY-27709 is active
against the other H1 subtype influenza virus (A/PR/8/
34) and against the H2 subtype A/Japan/307/57 virus.
However, it did not show any significant activity against
the two H3 subtype (A/HK/8/68, A/Udorn/307/72) viruses
tested. In addition, BMY-27709 did not exhibit inhibitory
activity against influenza B/Lee/40 virus in a plaque re-
duction assay (data not shown). BMY-27709 also had no
apparent activity against Vesicular Stomatitis Virus or
Herpes Simplex Virus in tissue culture assays (data not
shown). This result suggests that BMY-27709 is specific
for influenza virus, but has a limited spectrum of activity
as the antiviral is restricted to H1 and H2 subtype HA
viruses. It further suggests that the antiviral activity of
BMY-27709 may be mediated through the HA protein of
influenza A virus. BMY-27709 was also tested against
recent isolates of H1 subtype viruses. As shown in Fig.
2B, both A/Taiwan/1/86 and A/Texas/36/91 are as sensi-
tive to inhibitor as A/WSN/33 and A/PR/8/34 viruses. This
suggests that the target of BMY-27709 is highly con-
served among H1 and H2 subtype viruses.
The target of BMY-27709 is the hemagglutinin protein
Since BMY-27709 is not active against H3N2 viruses,
reassortant viruses between H1N1 and H3N2 viruses
can be used to map the resistance marker. HK-WSN virusFIG. 1. (A) Structure of BMY-27709. (B) Activity of BMY-27709 against
is a laboratory reassortant virus containing seven geneinfluenza A/WSN/33 virus in tissue culture. Thirty to 50 PFU of influenza
A/WSN/33 virus was used to infect 1 well of MDBK cells in a 96-well segments from A/WSN/33 virus and the HA gene seg-
plate. At 1 hr p.i., cells were incubated with various amounts of BMY- ment from A/HK/8/68 virus (Schulman and Palese , 1976).
27709 for 3 more days. Percentage of cells protected from virus infec- If BMY-27709 inhibition of virus replication is mediated
tion by BMY-27709 was determined through MTT staining.
through the HA protein, then it should have no effect
upon the growth of HK-WSN virus. MDBK cells were in-
fected with either the reassortant HK-WSN or A/WSN/33multicycle growth assay where actual virus yield was
virus at a low multiplicity (m.o.i.  0.0002) and incubatedmeasured, the virus yield dropped nearly 100-fold at a
with various amounts of BMY-27709 for 3 days. The viral4.7 mM concentration of BMY-27709 (Fig. 3).
yield was subsequently determined by a plaque assay.
As shown in Fig. 3, BMY-27709 dramatically reduced theSpecificity studies on BMY-27709
viral yield of influenza A/WSN/33 virus greater than 3
Since BMY-27709 is a potent inhibitor of A/WSN/33
logs at 75.8 mM. It should be noted that HK-WSN virus
virus in tissue culture, experiments were performed to
does not normally produce high titers in MDBK cells.
determine if BMY-27709 inhibits other subtypes of influ-
Even so, the growth of HK-WSN reassortant virus was not
enza virus. Three different HA (H1, H2, and H3) subtype
significantly affected by BMY-27709 at any concentration
and 2 different NA (N1 and N2) subtype viruses are found
tested. These data demonstrate that the inhibition effect
to circulate in humans (Murphy and Webster, 1990, Web-
caused by BMY-27709 is mediated through either a direct
ster et al., 1992). At the present time, both H1N1 and
or an indirect effect on the HA protein.
H3N2 subtype influenza A viruses are cocirculating in
the population (Murphy and Webster, 1990, Webster et BMY-27709 acts at an early stage in the replication
al., 1992). In order to determine if BMY-27709 inhibits cycle
the other subtypes of human influenza A virus, plaque
reduction assays were performed. MDCK cells were in- The hemagglutinin protein has multiple functions at
both early and late stages of virus infection. In an effort tofected with 50–100 PFU each of the following viruses:
influenza A/PR/8 (H1N1), A/Japan/305/57 (H2N2), A/HK/ probe the molecular mechanism underlying the antiviral
activity of BMY-27709, time of addition experiments were8/68 (H3N2), and A/Udorn/307/72 (H3N2) viruses. Virus-
infected MDCK cells were overlaid with agar-containing performed under single cycle growth conditions. MDBK
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FIG. 2. (A) Specificity of BMY-27709 for inhibition of different HA subtypes of human influenza A virus. Approximately 50 PFU of each virus were
used to infect one 35-mm2 dish of MDCK cells. At 1 hr P.I., 2.5 ml of agar overlay media containing various concentrations of BMY-27709 was
added onto cells. After 3 days incubation at 377, cells were stained with 0.1% crystal violet/20% methanol. The concentration (mM) of BMY-27709
is indicated on the top. Virus strains are indicated: PR8 (A/PR/8/34; H1N1), Japan (A/Japan/305/57; H2N2), Udorn (A/Udorn/307/72; H3N2), and Hong
Kong (A/HK/8/68;H3N2). (B) Same as A, except viral strains examined (A/Taiwan/1/86 and A/Texas/36/91) are recent H1 clinical isolates. The
concentration (mM) is indicated on the left.
cells were infected with influenza A/WSN/33 virus at an viral replication at an early step in the infection process.
Since its effect is mediated through functions of the HAm.o.i.  2 and either 2.4 or 75.8 mM BMY-27709 was
added during the infection process (0 hr), or at 1, 3, and protein, likely candidates for inhibition include receptor
binding (attachment) of virus or the membrane fusion5 hr postinfection. Virus yield in the supernatant was
determined after 14 hr incubation. The results show that event (uncoating). From these results, it is unlikely that
BMY-27709 has any effect on the late functions of hemag-BMY-27709 is only active when it was added at an early
time of infection (Fig. 4). Approximately 100-fold lower glutinin, such as virion assembly and maturation.
titers were obtained when compound was added during
the infection and maintained afterward (0 hr; Fig. 4). Addi- Genetic analysis of drug resistance
tion of compound 1 hr after infection reduced viral yields
in a single cycle by approximately 10-fold. No significant In order to further elucidate the mechanism of action
of BMY-27709, efforts were made to isolate BMY-27709-effect of BMY-27709 on virus yield was observed when
it was added at 3 and 5 hr of postinfection (3 and 5 hr; resistant viruses. Influenza A/WSN/33 virus was propa-
gated for two passages at low multiplicity in the presenceFig. 4). These results suggest that BMY-27709 blocks
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FIG. 3. BMY-27709 targets the HA protein. A reassortant virus, HK-
WSN, differs from A/WSN/33 (H1 HA) virus only in the HA gene, which
is derived from influenza A/HK/8/68 (H3 subtype) virus. About 30–50
PFU of either A/WSN/33 virus or HK-WSN virus was used to infect
MDBK cells. At 1 hr p.i., cells were incubated with a concentration of
either 0, 1.2, 4.7, 18.9, or 75.8 mM of BMY-27709 for 3 days. The superna-
tant was harvested and virus yield was determined by plaquing on
MDCK cells. Virus yield is plotted in log scale against concentration
of BMY-27709.
virus. Two nucleotide changes were found in both the
wild-type and resistant clone compared to the published
sequence (Hiti et al., 1981). These changes are C r U
at nucleotide 629 and G r A at nucleotide 1200 in the
coding strand. The former change does not result in an
FIG. 2—Continued
of 38 and 75.8 mM BMY-27709 and plaque purified in
the presence of compound. Three independent resistant
viruses were isolated. One of them was shown to be
highly resistant to BMY-27709, and was characterized in
more detail. In a multicycle growth experiment, BMY-
27709 did not significantly reduce the virus yield of the
resistant virus at concentrations up to 75.8 mM. The IC50
for this resistant virus was estimated to be more than
100 times higher when compared to that for wild-type
virus (data not shown). Subsequently, this resistant virus FIG. 4. BMY-27709 acts at an early stage of infection. MDBK cells
in a 35-mm2 dish were infected with influenza A/WSN/33 virus at awas amplified and the vRNA was extracted. Using spe-
multiplicity of infection (m.o.i) of 2. BMY-27709 was added at one ofcific oligonucleotide primers, the HA gene of the resistant
two concentrations: 2.4 mM (open bar) or 75.8 mM (solid bar) eithervirus was amplified, cloned, and subsequently se-
during infection (0 hr) , 1, 3 or 5 hr p.i. At 14 hr p.i., the supernatant of
quenced. Two independent HA cDNA clones were se- virus-infected cells was collected and virus yield was determined by
quenced, along with a newly amplified and cloned HA plaquing on MDBK cells. Control refers to virus yield without BMY-
27709 treatment.gene from the WSN stock used to make the resistant
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amino acid change while the latter change at nucleotide of virus to the sialic acid receptor on the cell surface as
well as the fusion of the viral and endosomal membranes1200 results in a glycine to arginine change at position
47 in the HA2 subunit. The two independent clones of (Wiley and Skehel, 1987, White, 1992). Since BMY-27709
targets HA function during an early stage of infection asthe resistant virus also share two novel nucleotide differ-
ences. One, a U r C transition at nucleotide 604 of the shown above, it could inhibit either the receptor binding
activity of HA or the HA-mediated membrane fusion pro-coding strand does not result in an amino acid change.
The second shared mutation is a U r C transition at cess. Hemagglutinin-inhibition (HI) tests with A/WSN/33
virus were performed in the presence of BMY-27709 tonucleotide 1390 of the coding strand, resulting in an
amino acid change from Phe to Ser at position 110 of determine if receptor binding activity of HA was effected
by BMY-27709. Results show that there was no inhibitionHA2 subunit. This nucleotide change was verified
through direct sequencing of the resistant virus RNA. It of hemagglutination at any drug concentration up to 600
mM of BMY-27709 (data not shown). Therefore, a hemo-should be noted that one of the cDNA clones, designated
pT7HA1, contains an additional G r A mutation at nucle- lytic assay was carried out in order to determine the
effect of the compound on inhibition of virus-mediatedotide 603 in the coding sense, which would result in an
amino acid change from Val to Ile at position 191 of the membrane fusion. In this assay, virus is first allowed to
bind to chicken red blood cells, and then incubated withHA1 subunit. However, this mutation is presumably a
cloning artifact and is not associated with drug resis- a low pH buffer (pH 5.0). As a result of the viral membrane
fusing with the membrane of the red blood cells, RBCstance, as it is present in only one of the two clones and
not present when virion RNA was sequenced directly. are lysed and hemoglobin is released and quantitated
by optical density measurement. The inhibition of HA-These results provide direct genetic evidence that a sin-
gle amino acid change from Phe to Ser at position 110 mediated hemolysis (membrane fusion) by BMY-27709
was determined by incubating various concentrations ofof the HA2 subunit generated the resistant phenotype.
compound with virus prior to addition of the RBC. TheRescue of the resistant phenotype through
results (Fig. 6) show that BMY-27709 specifically inhib-construction of a transfectant virus
ited the hemolysis mediated by both influenza A/PR/8
In order to prove that the amino acid change at position (H1N1) and A/Singapore/57 (H2N2) viruses. However, it
110 is responsible for drug resistance and to rule out did not significantly inhibit X31 (H3N2) virus in this assay.
that possible mutations in other genes may contribute to Also, BMY-27709 inhibited the virus-mediated hemolysis
the resistant phenotype, an attempt was made to rescue in a concentration-dependent manner. However, no inhi-
the cloned HA gene into an infectious virus. This is possi- bition was observed when the BMY-27709 drug-resistant
ble through the use of recently developed reverse genet- transfectant was used (Fig. 7). Therefore, these results
ics (Luytjes et al., 1989, Enami et al., 1990, Luo and demonstrated that BMY-27709 inhibits influenza virus in-
Palese, 1992). To achieve this, HA RNP complexes were fection by inhibiting the HA-mediated fusion of viral and
reconstituted in vitro from RNA transcribed from EarI- cellular membranes.
digested pT7HA1 DNA (resistant HA) or pT7HAV DNA
(wild-type HA) in the presence of viral polymerase pro-
DISCUSSIONteins and nucleoprotein. HA RNP complexes were then
transfected into MDBK cells which were infected with Several lines of evidence described here show that
the influenza A reassortant virus, HK-WSN. Transfectant the benzamide derivative, BMY-27709, is an HA-specific
viruses containing the rescued H1 subtype HA gene inhibitor of influenza A virus. First of all, BMY-27709 spe-
were isolated by serial passage in the presence of anti- cifically inhibited influenza A virus growth in tissue cul-
sera against H3 subtype HA virus. Transfectant viruses ture but did not possess inhibitory activity against influ-
were obtained and their identities were verified through enza B virus and another enveloped RNA virus, vesicular
direct RNA sequencing of HA gene. The transfectant vi- stomatitis virus (VSV, data not shown). It is also inactive
ruses were then tested for their sensitivity to BMY-27709 against a DNA virus, herpes simplex virus 1 (HSV-1, data
in a plaque reduction assay. The transfectant virus con- not shown). In addition, the antiviral activity of BMY-27709
taining the HA RNA derived from the resistant virus re- was found to be HA subtype-dependent. It inhibits the
tained the resistant phenotype, while the transfectant
replication of influenza A virus of either H1 or H2 sub-
virus containing wild-type HA is still sensitive to BMY-
types but it does not have significant activity against
27709 (Fig. 5). This data confirms the conclusion that the
H3 subtype virus. A reassortant virus (HK-WSN) with a
amino acid change in the HA2 subunit is responsible for
specific H3 subtype HA is resistant to BMY-27709, dem-
the drug-resistant phenotype.
onstrating that the HA protein is the direct target of BMY-
Inhibition of virus-mediated hemolysis by BMY-27709 27709. Furthermore, a resistant virus could be isolated
through serial passage in the presence of increasingThe HA protein of influenza virus plays a pivotal role
in initial stages of virus infection. It mediates the binding concentrations of BMY-27709. The virus isolated is highly
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FIG. 5. The Phe110 r Ser mutation is responsible for resistance to BMY-27709. The rescue of the wild-type HA gene segment or the HA clone
derived from the BMY-27709 resistant virus by reverse genetics resulted in transfectant viruses, wt HA, and resistant HA, respectively. Approximately
50–100 PFU of either wt HA transfectant, BMY-27709-resistant virus, or resistant HA transfectant were added to 35-mm2 dishes and incubated at
377 for 1 hr. At 1 hr p.i., virus-infected cells were overlaid with 2.5 ml of REM agar containing various concentrations of BMY-27709. At 2 days p.i.,
agar was removed and cells were stained with 0.1% crystal violet/20% methanol. The concentration of BMY-27709 is indicated on the left and each
virus is shown on the top.
resistant to BMY-27709 and was found to contain a single the resistant phenotype was proven through reverse ge-
netics, since transfectant virus containing the resistantamino acid mutation from Phe to Ser at position 110 of
the HA2 subunit. That this mutation was responsible for HA gene retained resistance to BMY-27709. This con-
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A/Texas/91, and H2 strains such as A/Japan/305/57 and
A/Singapore/57. The sensitivity of all these various H1
and H2 strains to BMY-27709 are nearly the same (Figs.
1 and 2 and unpublished data). In fact, the recent field
strains, A/Taiwan/86 and A/Texas/91, are more than 50
years apart from the lab-adapted strains A/WSN/33 and
A/PR/8, but sensitivity to BMY-27709 is still conserved.
In contrast, all H3 subtype strains including A/Hong
Kong/68, A/Victoria/8/75, and A/Udorn/307/72 are resis-
tant to BMY-27709.
Time of addition experiments suggest that BMY-27709
only inhibits virus growth when added at the early stage
of infection. Early functions of the hemagglutinin (HA)
protein consist of receptor binding and viral-endosomal
membrane fusion. In vitro receptor binding assays failed
to show any inhibitory activity of BMY-27709, suggesting
that the viral–cell fusion process is inhibited by BMY-
27709. One possibility is that BMY-27709 may act as a
general base to buffer the gradually decreasing pH of
FIG. 6. Specificity of hemolysis inhibition by BMY-27709. Approxi-
the endosome. However, studies have eliminated thismately 6 mg of either influenza A/PR/8/34 (H1N1), A/Singapore/57
possibility, as BMY-27709 does not have significant buff-(H2N2), or X31 (H3N2) virus was preincubated with BMY-27709 at a
concentration of 0, 18.5, 74, 148, and 296 mM at 377 for 1 hr, followed ering capacity (data not shown). The fact is, in vitro virus-
by addition of 200 ml of 2% chicken RBC. After a 10-min incubation at mediated red blood cell hemolysis (fusion) experiments
377, the reaction was treated with a low pH (5.0) buffer, and incubated described in Figs. 6 and 7 demonstrate that BMY-27709
at 377 for an additional 15 min. After neutralization to pH 7.0 { 0.2, the
specifically inhibits the hemolysis of red blood cells me-degree of RBC lysis resulting from fusion of viral and RBC membranes
diated by either H1 or H2 subtype, but not H3 subtypewas monitored by measuring optical density (O.D.) at 540 nm. The O.D.
value is plotted against concentration (mM). Influenza A/PR/8 (H1N1) viruses. This is entirely consistent with its specificity in
virus is shown by open circle (s), A/Singapore/57 (H2N2) virus by solid tissue culture. Previously, a group of fusion inhibitors
triangle (m), and X31 (H3N2) virus by solid circle (l). of the H3 HA were identified using a structure-based
computer modeling program (DOCK; Bodian et al., 1993).
firmed that the mutation from Phe to Ser at position 110 in
the HA2 subunit directly caused BMY-27709 resistance.
Taking all these results together, it could be firmly estab-
lished that BMY-27709 inhibits a function of the HA pro-
tein which enables it to inhibit the growth of H1 and H2
subtypes of influenza virus in tissue culture.
The HA subtype-dependence of the inhibitory activity
of BMY-27709 is probably determined by the divergence
of the amino acid sequence of the HA protein among
different HA subtypes (Webster et al., 1992). H1 and H2
subtype HAs are more closely related, sharing nearly
70% overall sequence homology. However, H1 and H3
or H2 and H3 subtype HAs are much less homologous,
with about 40% similarity overall (Nobusawa et al., 1991).
The sensitivity of H1 virus to BMY-27709 can also be
altered by a single amino acid change, as shown by the
Phe to Ser at position 110 of the HA2 subunit. Interest-
ingly, both H1 and H2 HAs contain a Phe residue at
position 110 of the HA2 subunit, while H3 HA molecules
code for a Leu residue at this position (Nobusawa et
al., 1991). This may explain why H3 subtype viruses are
FIG. 7. Drug-resistant virus is also resistant to BMY-27709 in a fusionresistant to BMY-27709. However, sensitivity to BMY-
assay. The assay is the same as described in the legend of Fig. 6
27709 is conserved among all H1 and H2 viruses tested. except that either A/WSN/33 virus (s) or the BMY-27709-resistant
BMY-27709 has been tested against various H1 strains, transfectant (l) was used. The virus was incubated with BMY-27709
at a concentration of 0, 2.4, 9.5, 37.9, and 151.5 mM at 377 for 1 hr.including the recent field strains, A/Taiwan/86 and
AID VY 8270 / 6a25$$$161 10-31-96 15:00:14 viras AP: Virology
75HEMAGGLUTININ-SPECIFIC INHIBITOR OF INFLUENZA A VIRUS
Cianci, C., Chung, T. D. Y., Meanwell, N., Putz, H., Hagen, M., Colonno,Evidence suggested that these quinone and hydroqui-
R. J., and Krystal, M. (1996). Identification of N-hydroxamic acid and n-none derivatives were able to inhibit the low pH-induced
hydroxy-imide compounds that inhibit the influenza virus polymerase.
conformational change in the H3 HA protein (Bodian et Antiviral Agents Chemother., in press.
al., 1993). Although a 3-D structure for the H1 protein is Colman, P. M. (1989). Neuraminidase, enzyme and antigen. In ‘‘The
Influenza Viruses’’ (R. M. Krug, Ed.), pp. 175–218. Plenum Press, NY.not yet available, through analogy with the H3 structure,
Colman, P. M. (1994). Influenza virus neuraminidase: Structure, Antibod-amino acid 110 of the HA2 subunit would be part of one
ies, and Inhibitors. Protein Sci. 3, 1687–1696.of the two a-helices in the native structure which are
Enami, M., Luytjes, W., Krystal, M., and Palese, P. (1990). Introduction
very close to the putative fusion peptide in HA2. One can of site specific mutations into the genome of influenza virus. Proc.
imagine that BMY-27709 may actually bind to a region Nat. Acad. Sci. USA 87, 3802–3805.
Enami, M., and Palese, P. (1991). High-efficiency formation of influenzanear the fusion peptide and Phe110 mutation, and
virus transfectants. J. Virol. 65, 2711–2713.thereby interfere with the viral–cell membrane fusion.
Hay., A. J. (1992). The action of amantadine against influenza A viruses;The characteristics of this HA-specific inhibitor of influ-
inhibition of the M2 ion channel protein. Semin. Virol. 3, 21–30.
enza A virus provides a potential novel target for anti- Hayden, F. G., Belshe, R. B., Glover, R. D., Hay, A. J., Oakes, M. G., and
influenza drug discovery. The unique mechanism used Soo, W. (1989). Emergence and apparent transmission of rimantad-
ine-resistant influenza A virus in families. N. Engl. J. Med. 321(25),by influenza virus for cell entry provides an opportunity
1696–1702.for identification of specific inhibitors which would block
Hayden, F., Treanor, J. J., Betts, R. F., Lobo, M., Esinhart, J., and Hussey,the fusion process. Presumably, all influenza virus sub-
E. (1996). Safety and efficacy of the neuraminidase inhibitor GG-167
types fuse with cellular membranes by a conserved in experimental human influenza. J. Am. Med. Assoc. 275, 295–299.
mechanism. The continued elucidation of the steps in- Hastings, J. C., Selnick, H., Wolanski, B., and Tomassini, J. E. (1996).
Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acidvolved in viral–cell fusion could provide new clues to-
inhibitors. Antimicrob. Agents Chemother. 40, 1304–1307.ward antiviral drug development (Carr and Kim,
Helenius, A. (1992). Unpacking the incoming influenza virus. Cell 69,1993,1994, Kemble et al., 1994, Pak et al., 1994, Bullough
577–578.
et al., 1994, Tatulian et al., 1995). The results described Hensens, O. D., Goetz, M. A., Liesch, J. M., Zink, D. L., Raghoobar, S. L.,
in this study validate that HA is indeed a viable target Helms, G. L., and Singh, S. B. (1995). Isolation and structure of fluti-
mide, a novel endonuclease inhibitor of influenza virus. Tetrahedronfor drug discovery, although BMY-27709 possesses too
Lett. 36, 2005–2008.narrow a spectrum of activity. It is hoped that further
Hiti, A. L., Davis, A. R., and Nayak, D. R. (1981). Complete sequenceinformation about the fusion process in general and the
analysis shows that the hemagglutinins of the H1 and H2 subtypes
mechanism of action of BMY-27709 in particular may of human influenza virus are closely related. Virology 111, 113–124.
allow for the generation of new chemotypes with activity Huang, T.-S.,. Palese, P., and Krystal, M. (1990). Determination of influ-
enza virus proteins required for genome replication. J. Virol. 64, 5669–over a broader range of HA subtypes.
5673.
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